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Purpose: Transoral robotic surgery (TORS) and laser 
microsurgery (TLM) have been utilized to perform lingual 
tonsillectomy in the diagnostic work-up of head and neck 
squamous cell carcinoma of unknown primary (CUP). We 
evaluated the potential therapeutic value for this approach by 
comparing differences in radiotherapy characteristics and 
clinical outcomes for CUP and small base-of-tongue (BOT) 
tumours. 
Methods and Materials: Retrospective review of BOT (T1N1-3M0) 
and CUP (T0N1-3M0) patients treated with intensity-modulated 
radiotherapy (IMRT) at our institution between 2005-2013 with 
known p16 immunohistochemistry status. The IMRT 
characteristics, mucosal (CTV-T) and nodal (CTV-N) clinical 
target volumes, and organ at risk (OAR) dosimetry, were 
obtained. Local (LC), regional (RC), distant control (DC), cause-
specific (CSS), overall survival (OS) and RTOG Grade ≥ 3 late 
toxicity (LT) were analyzed.  
Results: Fifty-four BOT (93% p16-positive) and 61 CUP (62% p16-
positive) patients were identified. Respective N classifications 
included: N1 (15 versus 8%), N2a (17 versus 31%), N2b (28 versus 
36%), N2c (24 versus 8%) and N3 (17 versus 16%). High-dose CTV-
T was prescribed in 100% of BOT and 38% of CUP patients (p < 
0.001). Low-dose CTV-T included mucosal sites outside of the 
oropharynx (i.e., nasopharynx, hypopharynx, and/or larynx) in 
0% of BOT and 26% of CUP patients (p < 0.001), with greater 
volume of low-dose CTV-T in CUP than BOT patients (113 ± 8 
versus 84 ± 6 cm3, p = 0.003). Bilateral neck irradiation was used 
in 53/54 (98%) BOT and 46/61 (75%) CUP patients (p < 0.001). 
OAR dosimetry demonstrated that BOT patients received higher 
maximum dose (Dmax) to the mandible (71 +/- 4.5 versus 67.2 
+/-  6.7 Gy, p = 0.001), with a trend toward higher laryngeal 
Dmax (66.1 +/- 7.6 versus 62.8+/-9.3 Gy, p = 0.059) and lower 
average dose (Dmean) to the larynx (43.8 +/- 7.5 versus 47.1 +/- 
10.7 Gy, p = 0.071). There were no significant differences in 
Dmax to inferior constrictor muscle or esophagus, and Dmean to 
mandible, inferior constrictor muscle or esophagus (p > 0.05 for 
all). The three-year LC, RC, DC, CSS and OS for p16-positive BOT 
versus CUP patients were 100% versus 95%, 98% versus 100%, 94% 
versus 91%, 94% versus 93%, 88% versus 91%, respectively, while 
in p16-negative BOT versus CUP patients were 75% versus 100%, 
75% versus 82%, 100% versus 85%, 75% versus 85%, 50% versus 74%, 
respectively (p > 0.05 for all). Grade 3 LT recorded in two (3%) 
CUP patients (neck fibrosis) and five (9%) BOT patients (two neck 
fibrosis, two osteoradionecrosis, and one dysphagia). 
Conclusions: Patients treated with IMRT for CUP or small BOT 
tumours had similar clinical outcomes. Performing TORS or TLM 
to identify small BOT tumours would lead to a reduction in the 
volume of low-dose CTV-T, with more frequent use of high-dose 
CTV-T and bilateral neck irradiation. Future studies are required 
to investigate the potential impact of these volumetric and 
dosimetric differences on quality-of-life and functional 
outcomes. 
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INFORMATION NEEDS OF PATIENTS DIAGNOSED WITH HEAD AND 
NECK CANCER UNDERGOING RADIATION THERAPY: A SURVEY OF 
PATIENT SATISFACTION  
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BC 
Purpose: A comprehensive revised patient education booklet, 
for patients diagnosed with head and neck cancer, was 
developed at our centre. This revised education booklet 
consolidates information from various sources in a single 
document. 
The objectives of this study are: 1) to identify patients’ reported 
informational needs and areas for improvement in patient 
education; and 2) to evaluate the level of patient satisfaction 
with the written information they received. 
Methods and Materials: A sample of 100 patients will be 
surveyed. The first cohort of patients will receive the original 
education material. The second cohort of patients will receive 
the education material revised. The survey will be administered 
to both cohorts of patients at two points during their treatment 
pathway: at the participants’ last radiation treatment 
appointment and at the six week follow up appointment.  
A satisfaction survey has been derived from the standard patient 
satisfaction survey currently in use at our institution. Survey’s 
questions evaluate several measures including content, amount, 
ease of understanding and timing of information delivery. 
Results: Data collection is currently ongoing. Qualitative 
responses will be reviewed and categorized using thematic 
analysis. Data from the two patient cohorts will be compared. 
Descriptive statistics will be used for quantitative analysis. 
Independent t-test will be used to test for differences between 
the two cohorts of patients. A rank-sum test will be used to 
determine whether the two groups of respondents differ in their 
average response. Within each cohort, a dependent t-test will be 
used to test for differences between the two time points at 
which the data is collected. 
Conclusions: The information gathered will be used to assess the 
usefulness of the new educational booklet compared to previous 
material. This may help develop site specific educational 
materials to improve our current practice and patient 
satisfaction. 
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Purpose: Definitive radiotherapy (RT) with or without 
chemotherapy has been the standard of care for early 
oropharyngeal cancer, achieving excellent oncologic outcomes 
but often with significant toxicities. Trans-Oral Robotic Surgery 
(TORS), a minimally invasive surgical approach, has emerged as 
a promising alternative with initial reports suggesting 
comparable oncological outcomes and excellent functional 
outcomes. Current studies are being performed to compare these 
two modalities in a head-to-head fashion; however, patient 
preferences regarding the choice of RT versus TORS are 
unknown. A Decision Aid was developed to navigate newly-
diagnosed patients through the complex process of deciding 
between the two treatment modalities to best suit their 
individual circumstances. 
Methods and Materials: A Decision Aid was developed on an 
interactive multimedia web platform to enable ease of access in 
multiple settings. It provides a visual description of the 
treatment modalities, including their respective timelines, and 
photographs of treatment-related equipment. Detailing of the 
potential benefits and side effects of each treatment was 
included, with their relative frequencies. Healthy adult 
volunteers (age 18-80) were recruited to pilot test the online 
module and confirm psychometric properties. Following a verbal 
description of a hypothetical diagnosis of early oropharyngeal 
cancer, subjects were guided through the Decision Aid with a 
trained researcher. Subjects were then asked to make a 
preferred treatment based on the assumption of equal 
oncological outcomes. Once established, the survival rate of the 
alternate therapy was increased to establish a treatment 
tradeoff point, in which the preferred strategy would switch. 
